Kangstem Biotech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Kangstem Biotech develops and manufactures stem-cell therapies, medicines derived from human umbilical cord blood that are designed to treat conditions such as atopic dermatitis, rheumatoid arthritis, and osteoarthritis.
It also develops exosome-based treatments targeting wound care, pneumonia, and hair loss. Alongside its clinical pipeline, the company supplies a cosmetics line built on its stem-cell culture technology, distributed primarily through online channels. Listed on KOSDAQ, Korea's tech and small-cap board, the business runs two main commercial segments, stem-cell therapeutics and cosmetics, while its drug pipeline remains in development.
Summary is AI-generated and may contain errors · figures from DART filings
Kangstem Biotech in five facts
What does Kangstem Biotech do?
Kangstem Biotech develops and manufactures stem-cell therapies, medicines derived from human umbilical cord blood that are designed to treat conditions such as atopic dermatitis, rheumatoid arthritis, and osteoarthritis.
Where is Kangstem Biotech listed and in which sector?
Kangstem Biotech (Korean name: 강스템바이오텍) trades under KRX code 217730 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Kangstem Biotech?
Its market capitalisation was US$139.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Kangstem Biotech's latest annual revenue and operating profit?
For fiscal year 2025, Kangstem Biotech reported revenue of US$2.7M, an operating loss of US$13.3M and a net loss of US$7.9M, per its annual report on DART (data retrieved from DART on 2026-09-18). Revenue was down 53.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingSep 30
- [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Kangstem Biotech updated its previously filed consolidated results for FY2025: revenue of US$2.42M (−53.9% year on year), an operating loss of US$12M and a net loss of US$7.09M.
Earnings · Mar 12 · 2 versions